Published in Cancer Weekly, August 19th, 2003
Researchers in South Korea conducted a study to "evaluate the potential of tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) to eradicate leukemia cell lines, while sparing normal hematopoietic stem cells."
"Human Jurkat and Molt-4 cell lines were used to optimize the purging process in umbilical cord blood (UCB) mononuclear cells," explained N.S. Lee and coauthors working at Soon Chun Hyang University Hospital in Seoul.
"The Jurkat cell line was TRAIL sensitive and TRAIL-resistant Molt-4 cell line became...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.